A brief description of the instructions for use of the Lao version of gilitinib generics

Gilteritinib (Gilteritinib), as an effective treatment for FLT3 mutation-positive acute myeloid leukemia (AML), its high price has always been the focus of patients. In order to alleviate this economic pressure, generic versions of giritinib have appeared on the Lao market, providing patients with more choices. The following is a brief description of the instructions for use of the Lao version of the generic version of Giritinib for patients’ reference.

1. Product information

The Lao version of gilteritinib generic is produced by a well-known local pharmaceutical company. The trade name may vary depending on the manufacturer, but the main active ingredient is Gilteritinib. The drug is available in various specifications, such as 40mg*90 tablets or 40mg*84 tablets, to meet the needs of different patients. Although the Lao version of the generic version of giritinib has been approved by the government, you still need to choose formal channels when purchasing drugs overseas and pay attention to distinguishing the authenticity of the drugs.

2. Indications

Giritinib is suitable for adult patients with relapsed or refractory AML carryingFLT3 mutations. This drug is a prescription drug, please consult your doctor before taking it.

3. Usage and dosage

The recommended dosage is 120 mg orally once a day, or adjust the dosage according to the guidance of your doctor. In the absence of disease progression or unacceptable toxicity, patients should receive treatment for at least 6 months to allow time for clinical response. Patients should take their medications at approximately the same time each day to ensure stable blood levels. Tablets should be swallowed whole and not broken, crushed or chewed. If you miss a dose, you should take it as soon as possible on the same day, but the interval between two doses should not be less than 12 hours.

4. Adverse reactions

When using the Lao version of giritinib generics, patients may experience some adverse reactions, including but not limited to nausea, vomiting, diarrhea, fatigue, fever, rash, etc. Most adverse reactions are mild to moderate and may gradually lessen or disappear as treatment continues. However, if serious adverse reactions or suspected allergic symptoms occur, the drug should be discontinued immediately and seek medical attention.

5. Things to note

Before using the Lao version of giritinib, patients should inform their doctor about all medications they are taking (including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements) to avoid drug interactions. Liver function and routine blood tests should be performed regularly during treatment to monitor the effects of the drug on the body. Pregnant and lactating women should use it with caution under the guidance of a doctor.

In short, the Lao version of giritinib generic provides a new treatment option for AML patients carryingFLT3 mutations. However, during use, patients should strictly abide by medical instructions and pay attention to the adverse reactions and precautions of the drug to ensure the safety and effectiveness of the treatment.